This subset harbours molecular alterations similar to those identified in a small cohort of ccRCC patients who benefit long term from mTOR inhibitor therapy56, and suggests a readily available targeted therapy venue for patients with advanced uRCC that belong to this subset. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.